Bio-Tech Systems Market Report
U.S. sales of diagnostic radiopharmaceuticals reached $1.69 billion
in 2005 and are expected to rise to $3.52 billion by 2012.
Radiopharmaceutical sales grew 8.1% in 2005, diminishing somewhat
from the previous year, but should resume growth in the range of
11%-12% per year. This forecast is based on the introduction of new
products for cardiology and oncology and continued growth of PET
imaging and sales of FDG. Sales of nuclear cardiology products will
continue to drive the radiopharmaceutical market, with high
utilization of nuclear perfusion studies coupled with advanced
pharmacologic stress agents and introduction of new products for
imaging myocardial infarction and congestive heart failure.
Therefore, nuclear cardiology sales of $1.21 billion in 2005 will
increase to $2.11 billion by 2012.
For additional information...
- APhA Officer Election Results
- Congratulations to the following
individuals for the recent election as APhA officers. We
appreciate their time and talents to serve our profession!
- New Election Cycle
- Just as the announcement is made
for the new APhA officers, it is now time to slate candidates
for the next election cycle. The APhA is changing the
election cycle so that members will be able to meet the
candidates at the APhA Annual Meeting and follow the same cycle
as the Board of Trustees elections. If you would like to
serve the nuclear section as an officer applications are due by
December 15th. Watch
www.aphanet.org for upcoming information.
- BPS Approved Live CE at APhA
- Live continuing education hours
applicable toward that which is required to maintain one's
certification as a Board Certified Nuclear Pharmacist through
the Board of Pharmaceutical Specialties has become a reality.
This will happen for the first time at the upcoming APhA annual
Meeting in Atlanta. Fifteen hours of live CE credit will
be offered for this meeting, of which five hours will be
accepted for recertification. More details about this
process to come.
- Hepatitis C Investigation
Reported in JAMA Article
- Health officials investigating
the October 2004 outbreak of hepatitis C among 16 Baltimore-area
recipients of a pharmacy-prepared radiopharmaceutical have
reported in the recent issue of the Journal of the American
Medical Association. This is an important lesson for
nuclear pharmacies handling biological products to follow
appropriate aseptic technique to prevent contamination of
To view this JAMA article...
2006, New York, NY
2007 Mid-Winter Meeting, San Antonio, TX
2007 Northern California Mid-Winter Meeting, Oakland,
March 16-19, 2007
2007 APhA Meeting in Atlanta, GA
37th Annual Mid-Eastern Chapter, SNM Spring Meeting, Ocean
Glow in the
things do not glow in the dark. Radiation
emitted by radioactive materials is not visible to
the human eye. However, there are ways to "convert"
this invisible energy to visible light. Many
substances will emit visible light if "stimulated"
by the ionizing radiation from radioactive material.
These materials are known as "fluors" or "scintilators."
So, by mixing some radioactive material, such as
tritium, with such a fluor, you can make a substance
that glows. This kind of material has been used in
things like the faces of clocks, watches, and
instruments on ships and airplanes to make them
visible in the dark. This is why most people think
of glowing things when they think of radioactive
New ! - Online
Nuclear Cardiologist Training
Most areas of the nation are
experiencing a pharmacist shortage. On average, how long does
it take to fill a pharmacist position in your pharmacy?
here to vote
Response to previous poll
"Does your pharmacy recognize and celebrate Nuclear Medicine Week
with your customers?"
A 32 year old patient with a
lumboperitoneal shunt presents with a recurrence of headaches.
A cisternogram was ordered to evaluate shunt patency.
If this email does not view graphics
properly go to
- © 2006 Nuclear Education Online
- 4301 W. Markham #522
- Little Rock, AR 72205
- To subscribe to this mailing
- To view